SENATE DOCKET, NO. 2093        FILED ON: 1/20/2023

SENATE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 660

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

John F. Keenan

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to the care and treatment of patients with mitochondrial disease.

_______________

PETITION OF:

SENATE DOCKET, NO. 2093        FILED ON: 1/20/2023

SENATE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 660

[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE SENATE, NO. 689 OF 2021-2022.]

The Commonwealth of Massachusetts

_______________

In the One Hundred and Ninety-Third General Court
(2023-2024)

_______________

An Act relative to the care and treatment of patients with mitochondrial disease.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

SECTION 1. Chapter 32A of the General Laws, as appearing in the 2020 Official Edition, is hereby amended by inserting after section 17R the following section:-

Section 17S. The commission shall provide to any active or retired employee of the commonwealth or spouse/dependent who is insured under the group insurance commission coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

SECTION 2. Chapter 175 is hereby amended by inserting after section 47NN the following section:-

Section 47OO. Any policy, contract, agreement, plan or certificate of insurance issued, delivered or renewed within the commonwealth shall provide coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

SECTION 3. Chapter 176A is hereby amended by inserting after Section 8OO the following section:-

Section 8PP. Any contract between a subscriber and a corporation under an individual or group hospital service plan delivered, issued or renewed within the commonwealth shall provide coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

SECTION 4. Chapter 176B is hereby amended by inserting after section 4OO the following section:-

Section 4PP. Any subscription certificate under an individual or group medical service agreement delivered, issued or renewed within the commonwealth shall provide coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

SECTION 5. Chapter 176G is hereby amended by inserting after Section 4GG the following section:-

Section 4HH. Any individual or group health maintenance contract shall provide coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.